These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11276802)

  • 21. Impact of Celecoxib restrictions in medicare beneficiaries with arthritis.
    Louder AM; Joshi AV; Ball AT; Cappelleri JC; Deminski MC; Sanchez RJ
    Am J Manag Care; 2011; 17(7):503-12. PubMed ID: 21819170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).
    Wynne HA; Campbell M
    Pharmacoeconomics; 1993 Feb; 3(2):107-23. PubMed ID: 10146960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
    Deeks JJ; Smith LA; Bradley MD
    BMJ; 2002 Sep; 325(7365):619. PubMed ID: 12242171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility analysis and economic burden of knee osteoarthritis treatment: the analysis from the real clinical practice.
    Turajane T; Chaweevanakorn U; Sungkhun P; Larbphiboonpong V; Wongbunnak R
    J Med Assoc Thai; 2012 Oct; 95 Suppl 10():S98-104. PubMed ID: 23451446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Celecoxib clinical profile.
    Tive L
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():21-8; discussion 57-9. PubMed ID: 11276798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Celebrex (celecoxib).
    Claussen DW
    Gastroenterol Nurs; 2000; 23(1):43-4. PubMed ID: 11096806
    [No Abstract]   [Full Text] [Related]  

  • 27. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
    Burke TA; Zabinski RA; Pettitt D; Maniadakis N; Maurath CJ; Goldstein JL
    Pharmacoeconomics; 2001; 19 Suppl 1():33-47. PubMed ID: 11280104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Celecoxib for rheumatoid arthritis.
    Garner S; Fidan D; Frankish R; Judd M; Shea B; Towheed T; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2002; (4):CD003831. PubMed ID: 12519610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New drug overview. Celecoxib.
    Am J Health Syst Pharm; 1999 May; 56(10):1031. PubMed ID: 10365731
    [No Abstract]   [Full Text] [Related]  

  • 30. Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease.
    Lee KK; You JH; Ho JT; Suen BY; Yung MY; Lau WH; Lee VW; Sung JY; Chan FK
    Aliment Pharmacol Ther; 2003 Jul; 18(2):217-22. PubMed ID: 12869082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.
    Cryer B; Luo X; Assaf AR; Sands G; Mardekian J
    Curr Med Res Opin; 2011 Feb; 27(2):295-302. PubMed ID: 21142617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis.
    McKenna F; Arguelles L; Burke T; Lefkowith J; Geis GS
    Clin Exp Rheumatol; 2002; 20(1):35-43. PubMed ID: 11892706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity.
    Juni P; Sterchi R; Dieppe P
    BMJ; 2003 Feb; 326(7384):334; author reply 334. PubMed ID: 12574052
    [No Abstract]   [Full Text] [Related]  

  • 34. Celecoxib--a rational alternative to NSAIDs.
    Moodley I; Hirsch G
    S Afr Med J; 2001 Jan; 91(1):36-40. PubMed ID: 11236293
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacoeconomic aspects of non-steroidal anti-inflammatory drug gastropathy.
    Walan A; Wahlqvist P
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S79-88. PubMed ID: 10379474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan.
    Yen ZS; Lai MS; Wang CT; Chen LS; Chen SC; Chen WJ; Hou SM
    J Rheumatol; 2004 Sep; 31(9):1797-803. PubMed ID: 15338503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharma-clinics. The drug of the month. Celecoxib (Celebrex)].
    Scheen AJ
    Rev Med Liege; 2001 Jan; 56(1):53-5. PubMed ID: 11256140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
    J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
    Clemett D; Goa KL
    Drugs; 2000 Apr; 59(4):957-80. PubMed ID: 10804043
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.